Form 8-K - Current report:
SEC Accession No. 0001213900-25-032732
Filing Date
2025-04-17
Accepted
2025-04-17 06:12:02
Documents
16
Period of Report
2025-04-17
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0238567-8k_cadrenal.htm   iXBRL 8-K 31824
2 OPINION OF BLANK ROME LLP ea023856701ex5-1_cadrenal.htm EX-5.1 12214
6 GRAPHIC image_001.jpg GRAPHIC 7525
7 GRAPHIC image_002.jpg GRAPHIC 7525
  Complete submission text file 0001213900-25-032732.txt   245726

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE cvkd-20250417.xsd EX-101.SCH 3014
4 XBRL LABEL FILE cvkd-20250417_lab.xml EX-101.LAB 34239
5 XBRL PRESENTATION FILE cvkd-20250417_pre.xml EX-101.PRE 22358
18 EXTRACTED XBRL INSTANCE DOCUMENT ea0238567-8k_cadrenal_htm.xml XML 3801
Mailing Address 822 A1A NORTH SUITE 306 PONTE VEDRA FL 32082
Business Address 822 A1A NORTH SUITE 306 PONTE VEDRA FL 32082 904-300-0701
Cadrenal Therapeutics, Inc. (Filer) CIK: 0001937993 (see all company filings)

EIN.: 880860746 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41596 | Film No.: 25844254
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)